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Clinics and pathology 
Disease 
In myeloid malignancies (acute myeloid leukemia 
(AML), myelodysplastic syndromes (MDS), chronic 
myelogenous leukemia (CML) as well as other 
myeloproliferative disorders), involvement of 3q26 in 
balanced rearrangements is highly suggestive of EVI1 
and/or MDS1/EVI1 rearrangement. As a consequence, 
balanced aberrations involving 3q26 are mainly 
detected in myeloid malignancies. 
Epidemiology 
3q26 rearrangements have been described in up to 5% 
of unselected patients with myeloid malignancies. 
Clinics 
Often associated with young age at diagnosis, trilineage 
dysplasia, dysmegakaryopoiesis and prior treatment 
with alkylating agents. 
Evolution 
In CML, emergence of an additional Ph+ clone with a 
3q26 rearrangement can be indicative of a pending 
disease transformation. 
Prognosis 
Generally 3q26 rearrangements are associated with 
adverse prognosis. This adverse prognosis probably 
correlates to the highly increased EVI1 expression, 
detectable in the vast majority of these patients. 
Whether 3q26 rearrangements, which are not 
associated with ectopic EVI1 expression share the same 
prognostic features, however, has not been addressed. 
Cytogenetics 
Cytogenetics morphological 
Although the frequently occurring balanced 3q26 
rearrangements can be readily identified by G-, Q-, or 
R-banding, the distal localisation makes it a good 
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candidate for involvement in cryptic aberrations. 
Rearrangements in which EVI1 and or MDS1/EVI1 
involvement have been well established include: 
- t(3;3)(q21;q26) 
- inv(3)(q21q26) 
- ins(3)(q26;q21q26) 
- t(3;12)(q26;p13) 
- t(3;21)(q26;q22) 
Recently we demonstrated EVI1 involvement in other 
recurrent rearrangements such as: 
- t(2;3)(p13-p23;q26) 
- t(3;6)(q26;q25) 
- t(3;13)(q26;q14) 
- t(3;17)(q26;q22) 
In addition, EVI1 is involved in more rare 
rearrangements such as inv(3)(p12q26)  
 inv(3)(q23q26) 
- t(3;3)(p24;q26)  
- t(3;5)(q26;q34) 
- t(3;9)(q26;p23) 
- t(3;12)(q26;q21) 
- t(3;18)(q26;q11) 
One should be aware of the fact, however, that in the 
majority of patients demonstrating ectopic EVI1 
expression, 3q26 rearrangements are generally not 
detectable cytogenetically. Whether in these patients 
cryptic aberrations cause EVI1 deregulation is currently 
under investigation. 
Cytogenetics molecular 
Breakpoint heterogeneity, with breakpoints mapping 3’ 
as well as 5’, of EVI1 impeded a sensitive detection of 
EVI1 rearrangement using molecular cytogenetic 
techniques. Recently, however, we studied numerous 
3q26 rearrangements using a 1.3Mb contig covering the 
EVI1 locus. We demonstrated sensitive and specific 
detection of EVI1 rearrangements using dual colour 
FISH using the following probe combinations: RP11-
82C9 and RP11-694D5 for 5’ rearrangements and 
RP11-82C9 and RP11-362K14 for 3’ rearrangements. 
Additional anomalies 
3q26 rearrangements are frequently associated with 
monosomy 7 and complex chromosomal aberrations. 
Genes involved and proteins 
EVI1, MDS1/EVI1 and MDS1 
Location 
3q26.2 
Note 
EVI1 and MDS1 display intergenic splicing, creating a 
PR domain member, MDS1/EVI1. Analogously to 
other PR domain genes, such as RIZ, MDS1/EVI1 and 
EVI1 are hypothesised to display antagonistic 
properties. Currently, experimental data are limited and  
conflicting indicating that further experiments are 
needed to clarify the exact role of both evolutionary 
conserved transcripts. 
DNA/RNA 
EVI1 spans approximately 50 kb and contains 12 
exons, 10 of which are coding. Translation starts in 
exon 3. MDS1/EVI1 results from intergenic splicing 
from MDS1 and EVI1, the resulting transcript 
MDS1/EVI1, contains the 2 first MDS1 exons spliced 
in frame to EVI1 exon 2. The MDS1 gene spans 
approximately 230 kb. 
Protein 
The EVI1 gene encodes a sequence specific Cys2/Hys2 
type 145kDa zinc finger protein, containing two sets of 
seven and three zing fingers, respectively. Alternative 
splicing creates a 88 kDa isoform that lacks the nuclear 
localisation signal and two zinc fingers. MDS1/EVI1 
encodes a PR domain family member. The PR domain 
is suggested to play an inhibiting role in tumorigenesis. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
Ectopic expression of an intact or truncated EVI1 
transcript has been reported as a result of 3q26 
rearrangements. Generally, 3q26 breakpoints map 3' to 
EVI1 in the inv(3) while the t(3;3) breakpoints more 
frequently reside 5' to EVI1. In addition expression of 
GR6/EVI1 and RPN1/EVI1 chimeras have been 
described in the t(3;3). Alternatively, AML1/MDS1, 
AML1/MDS1/EVI1 and AML1/ EVI1 fusion 
transcripts are produced by the t(3;21)(q26;q22), while 
ETV6/MDS1/EVI1 and ETV6/EVI1 fusions are related 
to the t(3;12)(q26;p13). The net effect of these 
rearrangements comprises an EVI1 gain of function: as 
a result of EVI1 ectopic expression or resulting from 
MDS1/EVI1 inactivation by disruption of its PR 
domain. 
Several hybrid genes resulting from 3q26 
rearrangements have been characterised and cloned, 
including the AML1/MDS1/EVI1 from the 
t(3;21)(q26;q22) and the ETV6/MDS1/EVI1 in the 
t(3;12)(q26;p13) these rearrangements are discussed 
elsewhere in the Atlas. 
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